GSK in talks with U.S. to lower drug prices

 GSK (NYSE:GSK) CEO Emma Walmsley said on Wednesday that her company is in discussions with the Trump administration on how to lower U.S. drug prices amid mounting pressure on pharmaceutical manufacturers to reduce their prices in line with those charged in other countries.

In May, President Donald Trump revived his most-favored-nation drug pricing policy, ordering the Department of Health and Human Services to negotiate with pharma companies on how to bring down the U.S. drug prices to levels in other developed nations.

According to Reuters, Walmsley said during a call with journalists that GSK’s (NYSE:GSK) discussions with the government center on “how to make sure discounts are passed on to patients and pricing is sustainable, both for the government and also for industry."

Her comments came after the British drugmaker reported better-than-expected financials for Q2 2025 earlier in the day.

GSK reported 46.5 pence per share of adjusted earnings on ~£8.0B in revenue with ~6% YoY and ~15% YoY growth in forex-adjusted terms, respectively, exceeding 42.8 pence per share and ~£7.8B projected by analysts, respectively, according to company-provided data.

The company also increased its full-year revenue and core earnings per share outlook to the top end of the previously indicated range of 3% - 5% and 6% - 8%, respectively.

https://www.msn.com/en-us/money/markets/gsk-in-talks-with-u-s-to-lower-drug-prices/ar-AA1JzJJG